Shots:
- Telix to acquire next-gen. therapeutic pipeline, biologics tech platform as well as research facility focused on protein engineering & discovery from ImaginAb via an asset purchase agreement to bolster its capabilities
- As per the terms, Telix will acquire candidates incl. DLL3 & integrin αvβ6 antagonist, plus a tech platform utilizing small engineered Ab format & a facility in California in exchange for $45M ($10M cash + $31M equity + ~$4M deferred equity payout after 15mos.)
- In addition, ImaginAb will also receive $185M as milestones in cash/equity, net-sales-based low single-digit royalties on limited platform & early-stage products after the development of 4 programs, plus single-digit sublicense fees
Ref: Telix Pharmaceuticals | Image: Telix Pharmaceuticals & ImaginAb
Related News:- Telix Spins Off Rhine Pharma to Broaden Global Radiopharmaceutical Reach
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
